IGM Biosciences Announces Refocusing of Sanofi Collaboration
April 17, 2024 08:30 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today...
IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum
April 10, 2024 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today...
IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 07, 2024 16:10 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today...
IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today...
IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today...
IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension
December 05, 2023 16:01 ET
|
IGM Biosciences, Inc.
– Priorities: clinical development of DR5 agonist in colorectal cancer and T cell engagers in autoimmune disease – – Plans to file IND for IGM-2644 (CD38 x CD3) to treat autoimmune disease – – All...
IGM Biosciences Announces Third Quarter 2023 Financial Results
November 13, 2023 16:10 ET
|
IGM Biosciences, Inc.
– Third IND cleared for imvotamab in autoimmune diseases – – International sites opened for aplitabart randomized clinical trial – MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- IGM...
IGM Biosciences to Present at Two Upcoming Investor Conferences
November 07, 2023 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z. Thompson, Ph.D. to Board of Directors
October 03, 2023 16:05 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
September 06, 2023 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...